Navigation Links
Use of Digoxin Associated with Higher Risk of Death for Patients Diagnosed With Heart Failure
Date:9/20/2013

801 deaths (737 off digoxin and 64 on digoxin). After adjustment for potential confounders, digoxin use was associated with a 72 percent higher relative rate of death.

There were 1,723 hospitalizations for heart failure overall (1,596 off digoxin, 127 on digoxin). However, after adjustment for potential confounders, digoxin use was not significantly associated with hospitalization for heart failure.

"Our community-based study population is more likely to represent patients with systolic heart failure in the modern era with regard to pathogenesis and treatment patterns," Dr. Go said. "Therefore, our results may more accurately represent the outcomes expected with digoxin for patients with systolic heart failure in typical present-day practices. As with all medication, treatment, or therapy plans, care decisions should always be made by physicians and their patients working together, with the patient's particular care needs and goals in mind."

Other authors on the study include James V. Freeman, MD, MPH of Yale University School of Medicine; Mark A. Hlatky, MD of the Stanford University School of Medicine; and Jingrong Yang, MA, and Sue Hee Sung, MPH, of the Division of Research, Kaiser Permanente Northern California.

About the Kaiser Permanente Division of Research
The Kaiser Permanente Division of Research (DOR) conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and the society at large. It seeks to understand the determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Currently, DOR's 600-plus staff is working on more than 250 epidemiological and health services research projects. For more information, visit www.dor.kaiser.org.

About Kaiser Perman
'/>"/>

SOURCE Kaiser Permanente
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medela Promotes Human Milk Consumption in NICUs to Address Health Risks Associated with Prematurity and Improve Infant Health
2. FDA Clears Hologics Single Energy Femur Exam to Visualize Features Associated with Developing Atypical Femur Fractures on a DXA Platform
3. OrbusNeich Launches Worlds First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents
4. Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
5. Forum Tackles the Rising Costs, Challenges and Diminished Outcomes Associated with Treating Obese Patients for Orthopaedic Conditions
6. American Association for Homecare Asks Associated Press To Correct Misleading Information In Story On Scooter Sales
7. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
10. Masimo Reschedules Release of Third Quarter 2012 Financial Results and Associated Conference Call to Thursday, November 1st Due to Hurricane Sandy
11. Anesthesia Equipment and Associated Peripherals: Advanced, Patient-Friendly Devices Will Sustain Market Growth in Europe, States Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical ... clinical trial scenario. This report provides elemental information and ... includes an overview of the trial numbers and their ... across the globe. The databook offers a preliminary coverage ... prominence of the sponsors and also provides briefing pertaining ...
(Date:9/18/2014)... London. (PRWEB) September 18, 2014 CD-adapco, ... Aided Engineering software, today announced its new partnership with ... utilizing the CD-adapco simulation tool, STAR-CCM+® in the design ... announced its participation in the 35th America’s Cup taking ... edition of the America’s Cup is sustainability, the set ...
(Date:9/18/2014)... This news release is available in German . ... at Technische Universitt Mnchen have won the ,International ... Hepatitis C Virus., As their prize, the scientists will ... the space station. The project involves crystallizing two proteins ... shuttle bringing these proteins to the International Space Station ...
(Date:9/18/2014)... According to a new market report published by Transparency ... Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” ... USD 77607.7 million in 2013 and is expected to grow ... reach an estimated value of USD 115474.9 million in 2020. ... at a rapid pace due to increasing prevalence of end ...
(Date:9/18/2014)... Norfolk, Virginia (PRWEB) September 18, 2014 ... in the START (Smart Teens Accepting Responsibility Today) Internship ... Stacie D. and Darcy C. describe the program as ... women had any idea about what they would be ... to get coffee, do food runs and other mindless ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4
... Hundreds ... HCG and how can it help us? , ... May 13, 2010 -- HCG, or human chorionic gonadotropin, is a natural hormone that is found in ... as energy for both the mom and her developing baby. , , , , ,Now, thanks ...
... ... cut from the USDA-NIFA budget, causing a concern among scientists about how urgent, near-term challenges ... (PRWEB) ... appeal to the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) ...
... ... InterHealth Canada,s three new Turks and Caicos clinical facilities allowing the islands to provide ... ... Telemedicine Inc, the worldwide leading supplier of telemedicine technology , devices, and application ...
... an increased risk of blindness, yet nearly half of the ... annual eye exam to detect possible problems. But ... problems related to diabetes can help meet the screening need, ... compared the ability of two sets of computer programs to ...
... ... House Appropriations Subcommittee to increase funding to federal programs supporting Meharry and the nation,s ... ... M.D., MPH, MBA, MACP, President & Chief Executive Officer of Meharry Medical ...
... can cause trouble, experts say , WEDNESDAY, May 12 (HealthDay ... implant and maintain could make life better for people who ... , A defibrillator delivers an electric shock to restart a ... implanted in Americans each year. Current models require careful surgery ...
Cached Medicine News:Health News:All About the HCG Drops Diet Program—What it is and Why it Works 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 3Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 4Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 2Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 3Health News:Computers can effectively detect diabetes-related eye problems 2Health News:Computers can effectively detect diabetes-related eye problems 3Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 2Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 3Health News:New Implanted Defibrillator May Be Simpler, Safer 2Health News:New Implanted Defibrillator May Be Simpler, Safer 3
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: